Author: Khawaja, Fareed; Chemaly, Roy F.
Title: Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies Document date: 2019_7_23
ID: 4fx18mlj_8
Snippet: In a cohort of 237 allogeneic HCT recipients with RSV infection, the hazard ratio (HR) of experiencing progression from RSV URTI to LRTI was 4.1 for an absolute neutrophil count of <500 cells/mL and 2.6 for an absolute lymphocyte count of <200 cells/mL, 53 making them the most predictive factors for progression. 53 Among leukemia patients, post-induction chemotherapy neutropenia and leukopenia have also been shown to increase the risk of progress.....
Document: In a cohort of 237 allogeneic HCT recipients with RSV infection, the hazard ratio (HR) of experiencing progression from RSV URTI to LRTI was 4.1 for an absolute neutrophil count of <500 cells/mL and 2.6 for an absolute lymphocyte count of <200 cells/mL, 53 making them the most predictive factors for progression. 53 Among leukemia patients, post-induction chemotherapy neutropenia and leukopenia have also been shown to increase the risk of progression to LRTI. 22, 24 In a recent retrospective study, neutropenia and lymphopenia were not independently associated with progression of disease in HM patients, but the combination of the two factors was associated with a higher risk of progression. 37 However, time from last chemotherapy was not shown to play a role in progression to LRTI in HM patients. 37 On the other hand, lack of ribavirin therapy was associated with progression of dishaematologica | 2019; 104(7) 37, 53, 58 The protective benefits of ribavirin are discussed further in the treatment section.
Search related documents:
Co phrase search for related documents- lymphocyte count and predictive factor: 1, 2, 3
- lymphocyte count and progression high risk: 1, 2, 3, 4, 5, 6, 7
- lymphocyte count and progression role: 1, 2
- lymphocyte count and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- lymphocyte count and ribavirin therapy: 1, 2, 3, 4
- lymphocyte count and RSV infection: 1, 2, 3, 4, 5, 6, 7
- lymphocyte count and RSV infection HCT recipient: 1
- neutrophil count and predictive factor: 1, 2, 3
- neutrophil count and progression high risk: 1, 2
- neutrophil count and progression role: 1
- neutrophil count and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- neutrophil count and ribavirin therapy: 1, 2, 3, 4
- neutrophil count and RSV infection: 1, 2, 3
- predictive factor and progression predictive factor: 1, 2
- predictive factor and progression role: 1
- predictive factor and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- predictive factor and RSV infection: 1
- progression high risk and retrospective study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- progression high risk and ribavirin therapy: 1
Co phrase search for related documents, hyperlinks ordered by date